Medicare advantage
Medicare advantage has been studied in 5 papers since 2023: 5 observational studies in people. The newest paper, Dec 31, 2024: “FUNCTIONAL OUTCOME IN HOME HEALTH AMONG TRADITIONAL MEDICARE AND MEDICARE ADVANTAGE BENEFICIARIES WITH DEMENTIA”.
5 papers study it8 findingsUpdated
See all 5 papers on medicare advantage
At a glance
The findings reach people, from one lab or study. 3 independent labs in 1 country.
“MA enrollees were 26% less likely to report improvement or maintenance of ADL composite score (95% CI: 0.71-0.77) than TM.”
None of its findings points the other way.
- 3 independent labs in 1 country
- Funders: National Institute on Aging and 2 more
- Humans5
What did studies of medicare advantage find?
7Studies of medicare advantage measured 7 outcomes, among them Home health visits, ADL composite score improvement or maintenance and gait speed.
Home health visits
no changein humans1
1 study
Home health visits
no changein humans1
Medicare advantage was not clearly linked with home health visits in humans during home health admission (2.14 vs. 2.13 visits, P=0.39).
“There was no difference in the number of HH visits between TM and MA enrollees (2.14 vs. 2.13; P=0.39).”
Humansduring home health admission
GSA 2024 abstract
ADL composite score improvement or maintenance
downin humans1
1 study
ADL composite score improvement or maintenance
downin humans1
Medicare advantage is linked with lower ADL composite score improvement or maintenance in humans during home health admission.
“MA enrollees were 26% less likely to report improvement or maintenance of ADL composite score (95% CI: 0.71-0.77) than TM.”
Humansduring home health admission
GSA 2024 abstract
Gait speed
no changein humans1
1 study
Gait speed
no changein humans1
Medicare advantage was not clearly linked with gait speed in humans (adjusted mean difference, -0.010 m/s [95% CI, -0.067 to 0.049 m/s]).
“there were no differences between MA and TM enrollees in the 1-year change in FI score (mean [SD], 0.016 [0.071] vs 0.014 [0.066]; adjusted mean difference, 0.001 [95% CI, -0.004 to 0.005]), FFP score (mean [SD], 0.017 [1.004] vs 0.007 [0.958]; adjusted mean difference, -0.009 [95% CI, -0.067 to 0.049]), SPPB score (mean [SD], -0.144 [2.064] vs -0.211 [1.968]; adjusted mean difference, 0.068 [95% CI, -0.076 to 0.212]), and gait speed”
Humans1 yearn = 7,063
Frailty in Medicare Advantage Beneficiaries and Traditional Medicare Beneficiaries
JAMA network open
Short Physical Performance Battery
no changein humans1
1 study
Short Physical Performance Battery
no changein humans1
Medicare advantage was not clearly linked with Short Physical Performance Battery in humans (adjusted mean difference, 0.068 [95% CI, -0.076 to 0.212]).
“there were no differences between MA and TM enrollees in the 1-year change in FI score (mean [SD], 0.016 [0.071] vs 0.014 [0.066]; adjusted mean difference, 0.001 [95% CI, -0.004 to 0.005]), FFP score (mean [SD], 0.017 [1.004] vs 0.007 [0.958]; adjusted mean difference, -0.009 [95% CI, -0.067 to 0.049]), SPPB score”
Humans1 yearn = 7,063
Frailty in Medicare Advantage Beneficiaries and Traditional Medicare Beneficiaries
JAMA network open
Fried frailty phenotype
no changein humans1
1 study
Fried frailty phenotype
no changein humans1
Medicare advantage was not clearly linked with Fried frailty phenotype in humans (adjusted mean difference, -0.009 [95% CI, -0.067 to 0.049]).
“there were no differences between MA and TM enrollees in the 1-year change in FI score (mean [SD], 0.016 [0.071] vs 0.014 [0.066]; adjusted mean difference, 0.001 [95% CI, -0.004 to 0.005]), FFP score”
Humans1 yearn = 7,063
Frailty in Medicare Advantage Beneficiaries and Traditional Medicare Beneficiaries
JAMA network open
Frailty index
no changein humans1
1 study
Frailty index
no changein humans1
Medicare advantage was not clearly linked with frailty index in humans (adjusted mean difference, 0.001 [95% CI, -0.004 to 0.005]).
“One year later, there were no differences between MA and TM enrollees in the 1-year change in FI score”
Humans1 yearn = 7,063
Frailty in Medicare Advantage Beneficiaries and Traditional Medicare Beneficiaries
JAMA network open
Physical function
no changein humans1
1 study
Physical function
no changein humans1
Medicare advantage was not clearly linked with physical function in humans (beneficiaries reporting rehabilitation) (-0.46 vs -0.21, p=0.069).
“MA beneficiaries had a similar decline in SPPB (-0.46 [SD 1.8] vs. -0.21 [SD 2.7], p-value 0.069) and adapted FIM (-1.05 [SD 3.7] vs. -1.13 [SD 5.45], p-value 0.764) compared to FFS.”
Humansbeneficiaries reporting rehabilitation
Long-term outcomes after rehabilitation in Medicare Advantage and fee-for-service beneficiaries
Journal of the American Geriatrics Society
What is medicare advantage linked with?
1Studies link medicare advantage with functional outcome.
Functional outcome
downin humans1
1 study
Functional outcome
downin humans1
Medicare advantage is associated with functional outcome in humans with Alzheimer's disease and related dementias during home health admission.
“MA enrollees were 26% less likely to report improvement or maintenance of ADL composite score (95% CI: 0.71-0.77) than TM.”
Humanswith Alzheimer's disease and related dementias during home health admissionn = 81,735
GSA 2024 abstract
Funding
1 grant since 2021Agency for Healthcare Research and Quality$1.5M